EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A. Nast; C. Smith; P. I. Spuls; G. Avila Valle; Z. Bata-Csörgö; H. Boonen; E. De Jong; I. Garcia-Doval; P. Gisondi; D. Kaur-Knudsen; S. Mahil; T. Mälkönen; J. T. Maul; S. Mburu; U. Mrowietz; K. Reich; E. Remenyik; K. M. Rønholt; P. G. Sator; M. Schmitt-Egenolf; M. Sikora; K. Strömer; O. Sundnes; D. Trigos; G. Van Der Kraaij; N. Yawalkar; C. Dressler

doi:10.1111/jdv.16926

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A. Nast^*, C. Smith, P. I. Spuls, G. Avila Valle, Z. Bata-Csörgö, H. Boonen, E. De Jong, I. Garcia-Doval, P. Gisondi, D. Kaur-Knudsen, S. Mahil, T. Mälkönen, J. T. Maul, S. Mburu, U. Mrowietz, K. Reich, E. Remenyik, K. M. Rønholt, P. G. Sator, M. Schmitt-EgenolfM. Sikora, K. Strömer, O. Sundnes, D. Trigos, G. Van Der Kraaij, N. Yawalkar, C. Dressler

^*Corresponding author for this work

Department of Clinical Medicine - The Department of Dermatology and Venereology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

133 Citations (Scopus)

79 Downloads (Pure)

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Original language	English
Journal	Journal of the European Academy of Dermatology & Venereology
Volume	35
Issue	2
Pages (from-to)	281-317
Number of pages	37
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.16926
Publication status	Published - Feb 2021

Access to Document

10.1111/jdv.16926Licence: CC BY-NC

Acad Dermatol Venereol - 2021 - Nast - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris Part 2 Final published version, 1.31 MBLicence: CC BY-NC

Library access?

Check availability with the Royal Danish Library

Cite this

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2021). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology & Venereology, 35(2), 281-317. https://doi.org/10.1111/jdv.16926

@article{e2e427652bd842ba8dc3973f4d8cc7d2,

title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations",

abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.",

author = "A. Nast and C. Smith and Spuls, {P. I.} and {Avila Valle}, G. and Z. Bata-Cs{\"o}rg{\"o} and H. Boonen and {De Jong}, E. and I. Garcia-Doval and P. Gisondi and D. Kaur-Knudsen and S. Mahil and T. M{\"a}lk{\"o}nen and Maul, {J. T.} and S. Mburu and U. Mrowietz and K. Reich and E. Remenyik and R{\o}nholt, {K. M.} and Sator, {P. G.} and M. Schmitt-Egenolf and M. Sikora and K. Str{\"o}mer and O. Sundnes and D. Trigos and {Van Der Kraaij}, G. and N. Yawalkar and C. Dressler",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology",

year = "2021",

month = feb,

doi = "10.1111/jdv.16926",

language = "English",

volume = "35",

pages = "281--317",

journal = "Journal of the European Academy of Dermatology & Venereology",

issn = "0926-9959",

publisher = "John Wiley & Sons Inc.",

number = "2",

}

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2021, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations', Journal of the European Academy of Dermatology & Venereology, vol. 35, no. 2, pp. 281-317. https://doi.org/10.1111/jdv.16926

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. / Nast, A.; Smith, C.; Spuls, P. I. et al.
In: Journal of the European Academy of Dermatology & Venereology, Vol. 35, No. 2, 02.2021, p. 281-317.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2

T2 - specific clinical and comorbid situations

AU - Nast, A.

AU - Smith, C.

AU - Spuls, P. I.

AU - Avila Valle, G.

AU - Bata-Csörgö, Z.

AU - Boonen, H.

AU - De Jong, E.

AU - Garcia-Doval, I.

AU - Gisondi, P.

AU - Kaur-Knudsen, D.

AU - Mahil, S.

AU - Mälkönen, T.

AU - Maul, J. T.

AU - Mburu, S.

AU - Mrowietz, U.

AU - Reich, K.

AU - Remenyik, E.

AU - Rønholt, K. M.

AU - Sator, P. G.

AU - Schmitt-Egenolf, M.

AU - Sikora, M.

AU - Strömer, K.

AU - Sundnes, O.

AU - Trigos, D.

AU - Van Der Kraaij, G.

AU - Yawalkar, N.

AU - Dressler, C.

N1 - Publisher Copyright: © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology

PY - 2021/2

Y1 - 2021/2

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

UR - http://www.scopus.com/inward/record.url?scp=85100540361&partnerID=8YFLogxK

U2 - 10.1111/jdv.16926

DO - 10.1111/jdv.16926

M3 - Journal article

C2 - 33547728

AN - SCOPUS:85100540361

SN - 0926-9959

VL - 35

SP - 281

EP - 317

JO - Journal of the European Academy of Dermatology & Venereology

JF - Journal of the European Academy of Dermatology & Venereology

IS - 2

ER -

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Abstract

Access to Document

Library access?

Other files and links

Fingerprint

Cite this